SUBSCRIBE
SUBSCRIBE

Phase I

Bristol-Myers Squibb's Stock Topples as Kidney Cancer Drug Flunks Phase III Study
Drug Development
FDA Slaps Partial Hold on 3 of Bristol-Myers Squibb’s Opdivo-Based Combo Trials
September 7, 2017
 · 
3 min read
Drug Development
Thiel-Backed Biotech Rational Vaccines Will Follow FDA Guidelines After Offshore Trial Controversy
September 5, 2017
 · 
1 min read
What You Missed: Nippon Fine Chemical Formed Human Barricade to Stop FDA Employee
Drug Development
Patient Dies in Cellectis’ Groundbreaking CAR-T Trial, Forcing a Halt to Trials
September 5, 2017
 · 
2 min read
AstraZeneca PLC Offloads Remaining Anesthetics Portfolio in $766 Million Deal
Drug Development
Investors Wait with Bated Breath for AstraZeneca PLC’s Cancer Trial Data Next Week
September 1, 2017
 · 
3 min read
Incyte Discloses Promising New Data in Combo Drug Trial With Merck & Co.'s Keytruda
Drug Development
Incyte Discloses Promising New Data in Combo Drug Trial With Merck & Co.'s Keytruda
August 31, 2017
 · 
3 min read
Drug Development
How A Potential Drug And A Possible M&A Could Drive Exelixis Even Higher
August 28, 2017
 · 
1 min read
Big-Name Investor Peter Thiel Funds ‘Unethical’ Offshore Herpes Vaccine Trial
Drug Development
Big-Name Investor Peter Thiel Funds ‘Unethical’ Offshore Herpes Vaccine Trial
August 28, 2017
 · 
2 min read
Investors Sigh With Relief as Biogen's Alzheimer's Drug Delivers in Early-Stage Study
Drug Development
Biogen Shows Off More Positive Alzheimer’s Trial Data
August 28, 2017
 · 
3 min read
Investors Sigh With Relief as Biogen's Alzheimer's Drug Delivers in Early-Stage Study
Drug Development
Biogen Gained $1 Billion Overnight After Becoming Goldman Sachs’ Favorite Biotech
August 17, 2017
 · 
3 min read
Drug Development
How To Try An Experimental Drug When You Don’t Qualify For A Clinical Trial
August 8, 2017
 · 
1 min read
Load More
PRESS RELEASES
Press Releases
OrsoBio Announces Nature Medicine Publication Establishing Clinical and Mechanistic Validation of First-in-Class LXR Inverse Agonist TLC-2716 for the Treatment of Serious Metabolic Diseases
January 16, 2026
 · 
4 min read
Press Releases
Nouscom Highlights Potential of NOUS-209 to Intercept Cancer in Lynch Syndrome Carriers in Seminal Nature Medicine Publication
January 16, 2026
 · 
8 min read
Press Releases
CASI Pharmaceuticals Announces Approval of Clinical Trial Application by China NMPA for Phase 1 / 2 Study of CID-103 for Renal Allograft Antibody-Mediated Rejection (AMR)
January 16, 2026
 · 
7 min read
Press Releases
AAVantgarde Completes Enrollment in LUCE-1 Phase 1/2 Clinical Trial of AAVB-081 for Usher Syndrome Type B-associated Retinitis Pigmentosa
January 16, 2026
 · 
4 min read
Press Releases
Caldera Therapeutics Launches with $112.5 Million and Announces First Subjects Dosed in Phase 1 Trial of First-In-Class Bispecific Antibody CLD-423 for Inflammatory Bowel Disease
January 15, 2026
 · 
2 min read
Press Releases
Solid Biosciences Provides 2026 Outlook Underscoring Neuromuscular and Cardiac Pipeline Momentum and Expanded Access to Next-Generation Capsid AAV-SLB101
January 14, 2026
 · 
10 min read
Press Releases
Marea Therapeutics Unveils Positive Topline Phase 1 Data for MAR002 in Acromegaly; Demonstrates Potential for Best-in-Disease Efficacy and Dosing Profile
January 13, 2026
 · 
6 min read
Press Releases
Pasithea Therapeutics Provides Outlook on PAS-004 Clinical Programs and Data Release Timelines
January 13, 2026
 · 
4 min read
Press Releases
Immunofoco Presents Phase I/IIa Data of IMC002 at ASCO GI 2026, Highlighting a Durable Complete Response Beyond One Year and a 66.7% ORR in Advanced GC/GEJ
January 13, 2026
 · 
5 min read
Press Releases
AbCellera Announces First Patients Dosed in Phase 2 Portion of its Phase 1/2 Clinical Trial of ABCL635 for the Treatment of Vasomotor Symptoms Due to Menopause
January 13, 2026
 · 
4 min read
Press Releases
CASI Pharmaceuticals Announces Update and Additional Results from Phase 1 Study of CID-103 in Adult Patients with Chronic Immune Thrombocytopenia
January 13, 2026
 · 
9 min read
Press Releases
BioAge Announces Additional Positive Interim Phase 1 Data for BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor, Demonstrating Potential for Best-in-Class hsCRP Reduction in Participants with Elevated Cardiovascular Risk
January 13, 2026
 · 
9 min read
Press Releases
Disc Medicine Highlights Recent Achievements and Key Business Objectives and Milestones for 2026
January 13, 2026
 · 
7 min read
Press Releases
Encoded Therapeutics Announces U.S. FDA Breakthrough Therapy Designation Granted to ETX101 for the Treatment of Dravet Syndrome
January 12, 2026
 · 
3 min read
Press Releases
Kivu Bioscience Announces First Patient Dosed in Phase 1 Trial of KIVU-107 Next-Generation PTK7-Targeting ADC for Advanced Solid Tumors
January 12, 2026
 · 
1 min read
Press Releases
CARsgen and Dispatch Bio Announce Clinical Collaboration to Evaluate Flare Platform and Zevor-cel in Solid Tumors
January 12, 2026
 · 
5 min read
Press Releases
IN8bio Presents Updated Phase I/II Data Demonstrating Meaningful and Durable Survival Improvements in Newly Diagnosed Glioblastoma
January 12, 2026
 · 
5 min read
Press Releases
Recludix Pharma Announces Dosing of First Subjects in a Phase 1 Study of REX-8756, a Potent and Selective Oral STAT6 Inhibitor, and Achieves Associated $20 Million Milestone Payment Under Collaboration with Sanofi
January 12, 2026
 · 
4 min read
Press Releases
Solid Biosciences Doses First Participant in First-in-Class Phase 1b FALCON Trial Evaluating SGT-212 Dual-Route Gene Therapy for the Treatment of Friedreich’s Ataxia
January 12, 2026
 · 
7 min read
Press Releases
Tessera Therapeutics Announces FDA Clearance of IND Application for its Lead In Vivo Gene Editing Program TSRA-196 for AATD
January 12, 2026
 · 
3 min read
Load More